ストックスクリーナーアプリを入手
2.51
5.91%
0.14
プレマーケット:
2.47
-0.04
-1.59%
前日終値:
$2.37
開ける：
$2.34
24時間の取引高:
35.84M
Relative Volume:
4.27
時価総額：
$780.19M
収益：
$160.03M
当期純損益:
$-128.58M
株価収益率:
-5.881
EPS:
-0.4268
ネットキャッシュフロー:
$-121.21M
1週間 パフォーマンス:
+58.86%
1か月 パフォーマンス:
+96.09%
6か月 パフォーマンス:
+85.93%
1年 パフォーマンス:
+81.88%
1日の値動き範囲:
$2.32
$2.555
1週間の範囲:
$1.52
$2.555
52週間の値動き範囲:
$1.07
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.51 | 503.55M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
96.69 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.44 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.96 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.23 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.19 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
PACB Stock Climbs As Traders Eye Conference Catalyst - StocksToTrade
Powered by PacBio: Selected publications from July – September 2026 - PacBio
Pacific Biosciences: Stock Surges As New Use Case SeenBut Caution Is Warranted (PACB) - Seeking Alpha
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat - StocksToTrade
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex - Yahoo Finance
Asset turnover of Pacific Biosciences of California, Inc. – HAN:P09 - TradingView
Why PacBio (PACB) Stock Is Trading Up Today - Yahoo Finance
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History - Yahoo! Finance Canada
PACB News | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
How to build the scientific case that gets your grant funded - PacBio
PACB Stock Firms Up Ahead Of Morgan Stanley Healthcare Chat - StocksToTrade
Pacific Biosciences of California (PACB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push - Yahoo Finance
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - Eastern Progress
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating - Moomoo
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
How to build a more competitive grant proposal without losing your research time to it - PacBio
Pacific Biosciences Coverage Assumed by UBS at Neutral - Moomoo
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks - The Globe and Mail
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? - Eastern Progress
PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference - marketscreener.com
PACB stock gains as PacBio highlights sequencing strength ahead Morgan Stanley conference - ad-hoc-news.de
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference - marketscreener.com
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test - TradingView
3 Reasons to Sell PACB and 1 Stock to Buy Instead - Yahoo Finance
Pacific Biosciences (PACB) Tumbles 9.7% to $1.40, Nears Critical Support at $1.33Stock News - vinanet.vn
PACB Q2 2026 Earnings: Wider-than-Expected Per-Share Loss Drives 9.68% SelloffEstimate Uncertainty - careplusvn.com
PACB Stock Pops As New CEO Backs Powerful Vega Upgrade - StocksToTrade
Pacific (PACB) Momentum: Ends Higher by 9.76% at $1.35 for the Current Session; Price Levels - careplusvn.com
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Pacific (PACB) Earnings Update: EPS Misses Its Estimate on the Day; Trading Response: Shares Close 11.40% Higher in Latest TradingEarnings Weakness Phase - Vinanet
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - Stock Titan
Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus
Pacific Biosciences of California Inc (PACB) (Q2 2026) Earnings - GuruFocus
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing (Aug 17, 2026) - Stock Titan
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - MarketBeat
ARK reports 9.59% stake in Pacific Biosciences (PACB) - Stock Titan
5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call - Yahoo Finance
PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs - Stock Titan
Measuring – not guessing – the true path - PacBio
Weekly Recap: PACB cuts 2026 revenue guide and Mark Van Oene named CEO - TradingView
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC - MarketBeat
Pacific Biosciences of California, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-08-08 - Seeking Alpha
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29 - simplywall.st
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen - MarketBeat
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
大文字化:
|
ボリューム (24 時間):